Inflammation-associated gene polymorphisms and clinical variables in the incidence and progression of retinopathy of prematurity.

INTRODUCTION: A growing body of evidence shows that genetics plays a vital role in the development and progression of retinopathy of prematurity (ROP). Perinatal inflammation is also considered an important risk factor of ROP. Therefore, understanding the interplay of genetics and susceptibility to inflammation might shed light on the pathogenesis of ROP and make its screening and treatment more effective in preventing visual impairment in premature infants.
MATERIAL AND METHODS: This study investigated the correlation of inflammation-associated gene polymorphisms: IL-1β +3953 C>T, IL-1RN VNTR 86 bp, IL-6 -174 G>C, IL-6 -596 G>A, and TNF-α -308 G>A as well as demographic and clinical characteristics of ROP in preterm infants (n = 90).
RESULTS: Our results demonstrate that IL-1RN rs2234663 1/1 genotype prevails in infants with ROP that regresses without intervention, when compared to those requiring laser photocoagulation/anti-VEGF injection (p = 0.031). Genotype 2/2 of IL-1RN occurs more frequently in children with severe ROP (28.6%) than in the group in which ROP regressed spontaneously (4.0%). The analysis revealed also differences between the genotypes of IL-1RN in ROP patients with intrauterine infection and in patients who had ROP without intrauterine infection; however, this was not statistically significant. Other studied polymorphisms were not associated with ROP development or its progression.
CONCLUSIONS: These results suggest that different genotypes of IL-1RN might have an impact on the course of ROP. Genotype 2/2 of IL-1RN gene may predispose to ROP progression.

Introduction

Despite screening guidelines based on the latest scientific reports and constantly perfected treatment procedures, retinopathy of prematurity (ROP) still ranks as one of the most significant causes of blindness in children throughout the world [1, 2]. Due to modern advances in neonatal care in developed countries, which enable the survival of extremely immature infants, ROP is becoming an increasing clinical and societal problem of contemporary paediatric health care. Regular examinations of children from high-risk groups permit early detection and treatment of progressive ROP, reducing future visual impairment. However, some children who develop ROP will suffer from retinal detachment despite screening and timely treatment. On the other hand, only about 30-40% of screened infants (< 1500 g) will develop ROP [3, 4], and an even fewer (1.5-9.5%) will require ophthalmological intervention [3, 5, 6]. In the remaining cases, ROP will never occur or will be self-limiting; but these children undergo numerous stressful examinations due to the existing guidelines. Hence, the incentive for a better understanding of the determinants of ROP, which would not only diminish the risk of visual impairment in the most susceptible infants but also limit the number of unnecessary check-ups.

Large multicentre studies have shown that low birth weight (BW), low gestational age (GA), and prolonged oxygen supplementation are the most important predictive factors of ROP development [7-10]. A variety of existing research enumerates additional potential risk factors such as low Apgar score, vaginal mode of delivery, intraventricular haemorrhage (IVH), necrotising enterocolitis (NEC), and bronchopulmonary dysplasia (BPD) [3, 11-14]. Furthermore, molecular studies have discovered the significant role of vascular endothelial growth factor (VEGF) in the pathogenesis of ROP [15]. However, despite these findings, ROP takes an unpredictable course in some infants, which might be due to their genetic makeup. Recent studies also show growing support for a link between both antenatal and neonatal exposure to inflammation and increased risk of ROP [16, 17]. Therefore, the need for closer investigation of the inflammation-associated genetic basis of this condition, which would help to identify infants predisposed to the disease itself and, even more importantly, its progression to the stages at which treatment is necessary and the risk of visual impairment is high.

The aim of this study was to evaluate the possible relationship between four single nucleotide polymorphisms (SNPs) of inflammation-linked genes encoding for interleukin 1 (IL-1β+3953 C>T), interleukin 6 (IL-6 -174 G>C and IL-6 -596 G>A), and tumour necrosis factor α (TNF-α-308 G>A) and variable number tandem repeat (VNTR) polymorphisms of interleukin-1 receptor antagonist (IL-1RN VNTR 86 bp) and the occurrence of ROP in a population of preterm infants. The demographic data and clinical characteristics of the study group were also reviewed.

Material and methods

The study followed the tenets of the Declaration of Helsinki and was approved by the Bioethics Committee of Poznan University of Medical Sciences (66/14 and 799/16).

Study population

Between 1st March 2014 and 11th June 2016, 402 premature infants were born from 22 +0 to 33 +0 weeks of gestation and admitted to the Neonatal Intensive Care Unit at Poznan University of Medical Sciences. Of these infants, 90 (22.4%) were found eligible for the study. Other infants were excluded due to an increased risk of complications of prematurity by one of the following factors: birth from multiple pregnancies, birth from pregnancies complicated by death of one of the foetuses, presence of chromosomal abnormalities, presence of inherited errors of metabolism, or death before 40 weeks of postmenstrual age. Also, children diagnosed with congenital infections from TORCH complex organisms (toxoplasmosis, other, rubella, cytomegalovirus, herpes) were excluded due to the potentially harmful effect of these infections on the eye such as chorioretinal scarring or active chorioretinitis. All infants and their parents were Caucasian, which ensured a degree of homogeneity of the study population. We included in the study group only patients who either underwent the series of retinal screening examinations and in whom further possibility of ROP development was minimal due to postmenstrual age of ≥ 40 weeks (when vascularisation of the retina should be complete or almost complete) or those who developed ROP. The children in whom ROP occurred were examined until either total regression of the condition or they received treatment and remained in systematic follow-up with our outpatient clinic after discharge from the hospital.

Retinopathy of prematurity diagnosis

Due to gestational age of less than 33 +0 weeks all enrolled infants met the criteria of the National Specialist Team in Paediatrics and School Medicine and Polish Ophthalmological Society for ROP screening (≤ 33 weeks of postmenstrual age, ≤ 1800 γ of birth weight, or on the request of neonatology specialist due to high risk of ROP) and underwent a series of ophthalmological examinations. The first examination was undertaken at four weeks of chronological age. Further examination was conducted depending on the condition of the eyes, every 7-10 days. Examinations continued until retinal vascularisation reached zone III, when the risk of a serious adverse outcome of ROP is minimal [18] or when the patient showed signs of ROP regression on at least two examinations. All examinations were performed by one of three paediatric ophthalmologists trained in the ROP screening procedure. The advancement of the disease, e.g. stage, zone, and the presence of plus disease and other meaningful changes, were assessed and documented according to International Classification of Retinopathy of Prematurity (ICROP) [19].

Retinopathy of prematurity treatment

The treatment criteria were based on the Early Treatment for Retinopathy of Prematurity guidelines [9], which were maintained by the American Academy of Paediatrics policy statement in 2013 [20]. Treatment was administered in the eyes of the patients with any stage of ROP in zone I with plus disease; zone I, stage 3 ROP without plus disease; or zone II, stage 2 or 3 ROP with plus disease. In other cases, a wait-and-watch approach was applied. Eyes were systematically examined and treated if progression occurred.

The decision on the treatment method was based on the most recent reliable scientific reports due to a lack of conclusive international guidelines. Laser photocoagulation of the peripheral avascular retina is the treatment standard in our centre. Yet, in severe zone I ROP we used intravitreal injection of ranibizumab, the anti-VEGF antibody, as an off-label therapy. The latest reports confirm the effectiveness of anti-VEGF monotherapy compared to laser ablation for zone I in infants with stage 3+ ROP [21]. However, this method is used with caution due to concerns regarding the short- and long-term safety of anti-VEGF treatment to ocular and neurologic development. Both procedures were performed after obtaining written, informed consent from the parents or legal guardians of the patients.

Studied polymorphisms

The selection criteria for candidate genes was based on their potential involvement in the pathogenesis of ROP. The products of the selected genes are the key mediators in the inflammatory process. Intrauterine infection is the most frequent cause of preterm birth, which accounts for around 40% of all cases [22]. It may cause foetal infection and inflammation, thus inducing the inflammatory response in both foetuses and newborns. Microorganisms and their toxins induce foetal production of IL-6 and other inflammatory markers such as IL-1 and TNF-α. They may distort retinal vascularisation leading to ROP development. Due to the significant role of Il-1, Il-6, and TNF-α in the process of inflammation and their possible link with ROP development, we concluded that the chosen polymorphisms may play a role in the pathogenesis of ROP.

We studied four SNPs: IL-1β+3953 C>T, IL-6 -174 G>C, IL-6 -596 G>A, and TNF-α-308 G>A and a variable number of tandem repeat (VNTR) polymorphisms IL-1RN VNTR 86 bp. Their characteristics are shown in Table 1.

Table 1

Description of the five studied polymorphisms in IL-1, IL-6, IL-1RN, and TNF-α genes

Gene symbol	Polymorphism	Sequence of primers	Restriction enzyme	Products
IL-1β (rs1143634)	+3953C>T	F 5`-gTT gTC ATC Aga CTT TgA CC-3`R 5`-TTC AgT TCA TAT ggA CCA gA-3`	TaqI(Thermo Scientific)	CC137,114 bpCT251,137,114 bpTT251 bp
IL-1RN (rs2234663)	VNTR 86 bp	F 5`-CTC AgC AAC ACT CCT AT-3`R 5`-TCC Tgg TCT gCA ggT AA-3		IL1RN*0 154 bpIL1RN*1 410pz bp IL1RN*2 240 bpIL1RN*3 500 bpIL1RN*4 325 bpIL1RN*5 595 bp
IL-6(rs1800795)	-174G>C	F 5`-ACA TgC CAA gTg CTg AgT CA-3`R 5`-AAT CTT TgT Tgg Agg gTg Ag-3	LweI(Thermo Scientific)	GG114,100 bpGC214,114,100 bpCC 214 bp
IL-6(rs1800797)	-596G>A	F 5`-ggA gTC ACA CAC TCC ACC Tg-3`R 5`-AAg CAg AAC CAC TCT TCC TTT ACT T-3	BseGI(BtsCI)(Thermo Scientific)	GG420 bp GA420,354,66 bpAA354, 66 bp
TNF-α (rs1800629)	-308G>A	5`-AAA Tgg Agg CAA Tag gTT TTg Agg ggC TTg5`-TAC CCC TCA CAC TCC CCA TCC TCC CTg ATC	FaqI (BsmFI)	GG86,45 bpGA131,86,45 bpAA131 bp

A 0.5 ml sample of blood was taken directly after the delivery and banked. Genomic DNA was extracted from blood leukocytes using QIAamp DNA Blood Mini Kit (QIAGEN Inc., Germany). Genotyping was performed using Restriction Fragment Length Polymorphism analysis of PCR-amplified fragments (PCR-RFLP) and gel electrophoresis. Written, informed consent for blood collection and genetic testing was obtained from the parents or legal guardians of the patients.

For detection of the IL-1β +3953C>T mutation, PCR was amplified with starters: F 5`-gTTgTC ATC Aga CTT TgA CC-3`; R 5`-TTC AgT TCA TAT ggA CCA gA-3` (PCR product 251 bp long) and hydrolysed with Taq I restriction enzyme (Thermo Scientific). The following genotypes were obtained: CC (137, 114 bp), CT (251, 137, 114 bp), and TT (251 bp). Replacement of cytosine with thymine leads to the occurrence of a rarer allele 2, which is connected with higher production of IL-1β.

For detection of the IL-6 -174 G>C mutation, PCR was amplified using the starters: F 5`-ACA TgC CAA gTgCTgAgT CA-3`, R 5`-AAT CTT TgTTggAgggTg Ag-3’ (PCR product 214 bp long) and hydrolysed with LweI restriction enzyme (Thermo Scientific). The following genotypes were obtained: GG (114, 100 bp), GC (214, 114, 100 bp), and CC (214 bp). The following starters were used for detection of the IL-6 -596 G>A mutation: F 5`-ggAgTC ACA CAC TCC ACC Tg-3` and R 5`-AAgCAg AAC CAC TCT TCC TTT ACT T-3’. The PCR products (420 bp long) were hydrolysed with BseGI (BtsCI) restriction enzyme (Thermo Scientific) and yielded the following genotypes: GG (420 bp), GA (420, 354, 66 bp), and AA (354, 66 bp). In our research we analysed IL-6 -174G>C and -596G>A polymorphisms. Both homozygotes CC of polymorphism IL-6 -174G>C and AA of polymorphism IL-6 -596G>A result in decreased production of IL-6.

The TNF-α-308G>A polymorphism was detected using the following starters: 5`-AAA TggAgg CAA Tag gTTTTgAggggCTTg-3’ and 5`-TAC CCC TCA CAC TCC CCA TCC TCC CTg ATC-3’ (TIBMolBiol). The PCR product (131 bp) was hydrolysed with FaqI (BsmFI) restriction enzyme, and the following genotypes were found: GG (86, 45 bp), GA (131, 86, 45 bp), and AA (131 bp). The consequence of replacement of guanine by adenosine in this polymorphism results in the loss of binding place for AP-2 transcription factor.

The 86 bp variable number tandem repeat polymorphism of IL-1RN VNTR 86 bp was analysed with PCR using the following starters: F 5`-CTC AgC AAC ACT CCT AT-3` and R 5`-TCC Tgg TCT gCAggT AA-3` (TiBMolBiol). It was possible to obtain products with lengths of: 154 bp (IL1RN*0), 410 bp (IL1RN*1), 240 bp (IL1RN*2), 500 bp (IL1RN*3), 325 bp (IL1RN*4), and 595 bp (IL1RN*5). The main role is played by the number of repeats of 86-bp sequences within intron 2 of the human IL-1 receptor antagonist gene. The number of repeats is of functional significance because these repeats contain binding sites for transcription factors.

Statistical analysis

The following factors that may associate with the development of ROP were studied: gender, gestational age (GA, weeks), birth weight (BW, grams), small for gestational age (SGA, defined as birth weight under third percentile), Apgar score (in first and fifth minute), type of delivery (vaginal birth vs. caesarean section), birth asphyxia (defined as Apgar score less than 6 at 10 minutes and pH < 7.0 or blood base excess [BE] <-15 mmol/l in cord blood), intrauterine infection (defined as positive culture in sterile originally accompanied by clinical symptoms or pneumonia developed in 48 hours after the birth), late onset infection (defined as pneumonia, sepsis or infection of urinary tract), type of ventilation support (non-invasive vs. conventional), and complications of prematurity (bronchopulmonary dysplasia [BPD], intraventricular haemorrhage [IVH], necrotizing enterocolitis [NEC]). The results are presented as percentages of categorical variables or median (range) for non-normally distributed continuous variables as tested by the Shapiro-Wilk test. A p-value of less than 0.05 was considered significant. The Fisher exact probability test, the χ2 test, Fisher-Freeman-Halton exact test, and χ2 test with Yates correction were used to evaluate association between ROP and categorical variables. Differences in non-normally distributed continuous variables were compared by the U Mann-Whitney test. Logistic regression analysis was used to estimate odds ratios (OR) and confidence intervals (CI) of 95%. Statistical analysis was performed using CytelStudio version 10.0, created on January 16, 2013 (CytelStudio Software Corporation, Cambridge, Massachusetts, United States), and Statistica version 10, 2011 (Stat Soft, Inc., Tulsa, Oklahoma, United States). The expected genotype frequencies were calculated from allele frequencies with the Hardy-Weinberg equilibrium.

Results

The median gestational age of the 90 enrolled children was 29 ±2 weeks (range 22-33), and the median birth weight was 1120 ±366 grams (range 510-2340). We found that 39 preterm infants, 20 males and 19 females (72 eyes; in six infants ROP was found only in a single eye), developed ROP in our study population. Treatment-requiring ROP was present in 14 infants (16% of total, 36% of ROP cases), 28 eyes (39% of eyes with ROP), and was managed with laser photocoagulation (11 children, 22 eyes), ranibizumab injection (two children, four eyes), or a combination of these two treatment methods (one child, two eyes), as clinically indicated. The clinical and demographic data of enrolled infants and the comparison among the groups of children with vs. without ROP and non-treatment-requiring vs. treatment-requiring ROP patients are shown in Table 2.

Table 2

Demographic and clinical characteristic of enrolled infants

Characteristic		No ROP(n = 51)	ROP(n = 39)	p	Non-treatment-requiring ROP(n = 25)	Treatment-requiring ROP(n = 14)	p
Female, n (%)		25 (49.0)	19 (48.7)	0.977a	12 (48.0)	7 (50.0)	0.831c
Gestational age (weeks)				< 0.0001a			0.218e
	median and range	30 (26-33)	26 (22-31)		27 (23-31)	25 (22-30)
	24-28 (n, %)	14 (27.5)	31 (79.5)		18 (72.0)	13 (92.8)
	29-32 (n, %)	37 (72.5)	8 (20.5)		7 (28.0)	1 (7.0)
Birth weight (gram)				< 0.0001b			0.077a
	median and range	1345 (790-2340)	860 (510-1500)		930 (610-1500)	810 (510-1300)
	< 750	0 (0.0)	9 (23.1)		3 (12.0)	6 (42.8)
	750-1000	9 (17.6)	16 (41.0)		11 (44.0)	5 (35.7)
	> 1000	42 (82.3)	14 (35.9)		11 (44.0)	3 (21.4)
Apgar score (median and range)
	1st minute	6 (1-10)	4 (1-9)	0.0001d	5 (1-9)	4 (1-6)	0.656d
	5th minute	8 (5-10)	7 (1-9)	0.0002d	7 (1-9)	7 (4-9)	0.226d
Mode of delivery, n (%)				0.578a			1.000e
	Vaginal	18 (35.3)	16 (41.0)		10 (40.0)	6 (42.8)
	Caesarean section	33 (64.7)	23 (59.0)		15 (60.0)	8 (57.1)
Mechanical ventilation (days) median and range		8 (1-53)	54 (3-146)	< 0.0001d	44 (3-101)	80 (3-146)	0.005d
Asphyxia (n, %)		3 (5.9)	5 (12.8)	0.440c	2 (8.0)	3 (21.4)	0.329e
Intrauterine infection (n, %)		24 (47.0)	22 (56.4)	0.379a	14 (56.0)	8 (57.1)	0.789c
Late-onset infection (n, %)		6 (11.7)	6 (15.4)	0.851b	4 (16.0)	2 (14.3)	1.000e
IVH (n, %)		11 (21.6)	23 (59.0)	0.0003a	11 (44.0)	12 (85.7)	0.028c
BPD (n, %)		6 (11.7)	20 (51.3)	< 0.0001a	11 (44.0)	9 (64.3)	0.378c
NEC (n, %)		8 (15.7)	9 (23.1)	0.538c	4 (16.0)	5 (35.7)	0.238e

χ2 test, β Fisher Freeman Halton test, c χ2 test with Yate’s correction, d Mann-Whitney test, e Fisher exact test, IVH – intraventricular haemorrhage, BPD – bronchopulmonary dysplasia, NEC – necrotising enterocolitis

The following frequencies of genotypes of IL1RN were found in infants with ROP without treatment: 1/1 – 64.0%, 1/2 – 32.0%, 1/3 – 0%, 2/2 – 4.0%, 2/3 – 0%. Corresponding frequencies in patients treated with laser/ranibizumab were: 1/1 – 42.8%, 1/2 – 28.6%, 1/3 – 0%, 2/2 – 28.6%, 2/3 – 0% (p = 0.086). There was a statistically significant higher prevalence of genotype 2/2 of IL-1RN (p = 0.031; OR 10.67 [0.984-115.7]) polymorphism in infants with ROP that required treatment with laser/ranibizumab compared to those without treatment. 2/2 genotype was also found in the only infant from our study population with ROP recurrence, who required a secondary line of treatment. No correlation was found between the occurrence of ROP or necessity of ROP treatment and the following polymorphisms: IL-1β+3953 C>T, IL-6 -174 G>C, IL-6 -596 G>A, and TNF-α-308 G>A. However, for both IL-6 polymorphisms the deviation from Hardy-Weinberg equilibrium was observed for ROP patients. The deviation was also present for IL-6 -596 G>A polymorphism for ROP patients not requiring treatment. Genotype and allele distributions of studied polymorphisms and the analysis for Hardy-Weinberg equilibrium in infants without and with ROP, and without and with ROP treatment, are shown in Table 3.

Table 3

Genotype distribution of studied polymorphisms and the analysis for Hardy-Weinberg equilibrium in infants without and with retinopathy of prematurity (ROP), and without and with ROP treatment

Genesymboldb SNP		Genotypes	No ROP(n = 51)observed/(expected)	ROP(n = 39)observed/(expected)	p	OR 95% CIp	Non-treatment-requiring ROP(n = 25)observed/(expected)	Treatment-requiring ROP(n = 14)observed/(expected)	p	OR 95% CIp
IL-1β+3953C>Trs1143634		CC	30 (28.3)	23 (23.1)	0.721a	Reference	12 (12.3)	11 (11.2)	0.225b	Reference
		CT	16 (19.4)	14 (13.8)		1.141 (0.420-3.08) 0.952	11 (10.5 )	3 (2.7)		0.298(0.043-1.606)0.207
		TT	5 (3.3)	2 (2.1)		0.522(0.046-3.585) 0.749	2 (2.3)	0 (0.2)		0.000(0.000-6.754)0.607
	HWE p		0.214	0.945			0.812	0.653
	Allele C		76	60	0.709a	Reference	35	25	0.097c	Reference
	Allele T		26	18		0.877(0.412-1.842)0.846	15	3		0.280(0.048-1.160)0.089
IL-1RN86 BP VNTRrs2234663		1/1	24 (22.7)	22 (20.1)	0.689b	Reference	16 (16)	6 (4.6)	0.086b	Reference
		1/2	18 (20.6)	12 (15.8)		0.727(0.257-2.032)0.665	8 (8)	4 (6.9)		1.333(0.211-7.670)1.000
		1/3	2	0		0.000(0.000-6.272)0.576	0	0		–
		2/2	6 (4.7)	5 (3.1)		1.309(0.285-6.232)0.948	1 (1)	4 (2.6)		10.67(0.984-115.7)0.031
		2/3	1	0		0.000(0.000-44.32)1.000	0	0		–
	HWE p		0.378	0.134			1.000	0.119
	Allele 1		68	56		Reference	40	16		Reference
	Allele 2		31	22	0.349b	0.862(0.425-1.733)0.779	10	12	0.059c	3.000(0.957-9.415)0.061
	Allele 3		3	0		0.000(0.000-3.051)0.343	0	0
IL-6-174G>Crs1800795		GG	13 (13.2)	7 (10.8)	0.217a	Reference	4 (6.3)	3 (4.6)	0.774a	Reference
		GC	26 (25.5)	27 (19.4)		1.929(0.595-6.619)0.340	17 (12.5)	10 (6.9)		0784(0108-6.525)1.000
		CC	12 (12.3)	5 (8.8)		0.774(0.150-3.797)0.995	4 (6.3)	1 (2.6)		0.333(0.005-7.204)0.849
	HWE p		0.886	0.015			0.072	0.086
	Allele G		52	41	0.833a	Reference	25	16	0.545a	Reference
	Allele C		50	37		0.939 (0.499-1.766)0.952	25	12		0.750(0.265-2.098)0.713
	IL-6-596G>Ars1800797	GG	15 (14.3)	7 (11.3)	0.053a	Reference	4 (6.8)	3 (4.6)	1.000a	Reference
		GA	24 (25.4)	28 (19.4)		2.5 (0.788-8.428)0.137	18 (12.4)	10 (6.9)		0.741(0.102-6.147)1.000
		AA	12 (11.3)	4 (8.3)		0.714(0.124-3.685)0.931	3 (5.8)	1 (2.5)		0.444(0.006-10.52)1.000
	HWE p		0.692	0.006			0.027	0.086
	Allele G		54	42	0.904a	Reference	26	16	0.0662a	Reference
	Allele A		48	36		0.964(0.512-1.816)1.000	24	12		0.813(0.287-0.273)0.843
	TNF-α-308G>Ars1800629	GG	40 (40.6)	27 (27.9)	0.341a	Reference	18 (18.5)	9 (9.5)	0.723a	Reference
		GA	11 (9.8)	12 (10.2)		1.616(0.558-4.684)0.454	7 (6)	5(4.1)		1.429(0.272-7.06)0.879
		AA	0 (0.6)	0 (0.9)		–	0 (0.5)	0 (0.4)		–
	HWE p		0.388	0.256			0.416	0.416
	Allele G		91	66	0.489c	Reference	43	23	0.900c	Reference
	Allele A		11	12		1.504(0.567-4.009)0.488	7	5		1.335(0.298-5.517)0.883

χ2, β Fisher-Freeman-Halton, c χ2 with Yates correction, HWE p – Hardy-Weinberg equilibrium p-value

The analysis revealed differences between the genotypes of IL-1RN in the patients with ROP and intrauterine infection and the patients with ROP and without intrauterine infection. The following frequencies of genotypes of IL-1RN were found in infants with ROP and intrauterine infection: 1/1 – 45.4%, 1/2 – 36.4%, 1/3 – 0%, 2/2 – 18.2%, 2/3 – 0%, and for patients with ROP and without intrauterine infection: 1/1 – 70.5%, 1/2 – 23.5%, 1/3 – 0%, 2/2 – 6.0%, 2/3 - 0%. Notably, 2/2 genotype of IL-1RN was more prevalent in infected vs. non-infected patients with ROP, but the difference was not statistically significant. We did not observe any association between intrauterine infection in patients with ROP and other studied polymorphisms. For both IL-6 polymorphisms the deviation from Hardy-Weinberg equilibrium was observed for patients without intrauterine infection and for ROP patients with intrauterine infection. Genotype distributions of studied polymorphisms and the analysis for Hardy-Weinberg equilibrium in infants without and with intrauterine infection, in ROP patients with intrauterine infection, and in patients that have ROP without intrauterine infection are shown in Table 4.

Table 4

Genotype distributions of studied polymorphisms and the analysis for Hardy-Weinberg equilibrium in infants without and with intrauterine infection; with retinopathy of prematurity (ROP) and without and with ROP and with intrauterine infection

Gene symboldb SNP		Genotypes	No infection(n = 44)observed(expected)	Infection(n = 46)observed(expected)	p	OR 95% CIp	ROP+no infection(n = 17)observed(expected)	ROP+infection(n = 22)observed(expected)	p	OR 95% CIp
IL-1β+3953C>Trs1143634		CC	28 (27.1)	25 (24.4)	0.678a	–	11 (9.9)	12 (13.2)	0.155a	–
		CT	13 (14.9)	17 (18.2)		1.465(0.543-3.99 )0.547	4 (6.1)	10 (7.7)		2.292(0.464-12.79)0.419
		TT	3 (2)	4 (3.4)		1.493(0.227-11.13)0.923	2 (1)	0 (1.1)		0.000(0.000-5.709)0.520
	HWE p		0.784	0.653			0.154	0.168
	Allele C		69	67	0.384a	Reference	26	34	0.393c	Reference
	Allele T		19	25		1.355(0.647-2.862)0.486	8	18		1.721(0.593-5.295)0.394
IL-1RN86 BP VNTRrs2234663		1/1	24 (23.6)	22 (19.3)	0.249b	–	12 (11.5)	10 (8.9)	0.342b	–
		1/2	15 (15.8)	15 (20.3)		1.091(0.393-3.024)1.000	4 (4.9)	8 (10.2)		2.4(0.455-14.0)0.411
		1/3	2	0		0.000(0.000-6.272)0.576	0	0		–
		2/2	3 (2.6)	8 (5.4)		2.909(0.589-18.83)0.249	1 (0.6)	4 (2.9)		4.8(0.369-255.7)0.372
		2/3	0	1		–	0	0		–
	HWE p		0.758	0.079			0.432	0.315
	Allele 1		65	59	0.258b	Reference	28	28	0.117c	Reference
	Allele 2		21	32		1.679(0.832-3.418)0.162	6	16		2.667(0.826-9.476)0.114
	Allele 3		2	1		0.551(0.009-10.88)1.000	0	0		–
IL-6-174G>Crs1800795		GG	9 (12.6)	11 (11.5)	0.379a	–	4 (5.3)	3 (5.5)	0.881a	–
		GC	29 (21.9)	24 (23)		0.677(0.210-2.152)0.632	11 (8.4)	16 (11)		1.939(0.263-15.67)0.720
		CC	6 (9.5)	11 (11.5)		1.5 (0.331-7.025)0.794	2 (3.3)	3 (5.5)		2.000(0.121-37.87)1.000
	HWE p		0.031	0.768			0.198	0.033
	Allele G		47	46	0.647a	Reference	19	22	0.606a	Reference
	Allele C		41	46		1.146(0.613-2.146)0.758	15	22		1.267(0.470-3.428)0.775
IL-6-596G>Ars1800797		GG	11 (14.2)	11 (11.5)	0.308a	–	4 (5.3)	3 (5.5)	0.881a	–
		GA	28 (21.6)	24 (23)		0.857(0.281-2.623)0.960	11 (8.4)	16 (11)		1.939(0.263-15.67)0.720
		AA	5 (8.2)	11 (11.5)		2.2(0.48-10.78)0.412	2 (3.3)	3 (5.5)		2.000(0.121-37.87)1.000
	HWE p		0.049	0.768			0.198	0.033
	Allele G		50	46	0.359a	Reference	19	22	0.606a	Reference
	Allele A		38	46		1.316(0.702-2.470)0.443	15	22		1.267(0.470-3.428)0.775
TNF-α-308G>Ars1800629		GG	31 (32)	36 (36.5)	0.472a	–	12 (12.4)	15 (15.6)	1.000a	–
		GA	13 (11.1)	10 (9)		0.662(0.226-1.906)0.544	5 (4.2)	7 (5.9)		1.12(0.233-5.699)1.000
		AA	0 (0.9)	0 (0.5)		–	0 (0.4)	0 (0.5)		–
	HWE p		0.250	0.408			0.477	0.375
	Allele G		75	82	0.433a	Reference	29	37	0.865c	Reference
	Allele A		13	10		0.704(0.260-1.858)0.572	5	7		1.097 (0.267-4.860)1.000

χ2, β Fisher-Freeman-Halton, c χ2

Discussion

As far as clinical characteristics of the study group are concerned, our data is in accordance with previous studies, in which the most important risk factors for ROP development were low BW and GA at birth as well as exposure to supplemental oxygen [23, 24].

The statistical analysis of our patients’ characteristics also indicated other variables that can be associated with ROP development, including: lower median Apgar score in the first and fifth minute, prolonged mechanical ventilation, IVH, and BPD. These findings are largely consistent with previously-published research involving ROP risk factors [3, 11-14]. The important clinically relevant finding was that the only two environmental variables that statistically significantly correlated with a progression to threshold ROP were IVH and the excessive use of oxygen; this has also been reported in previous studies [3]. However, not all infants with prolonged ventilation develop ROP and even fewer require treatment. It remains uncertain whether IVH has an impact on ROP progression or if it co-exists with ROP. Despite extensive research, it is still not well understood why ROP progresses to severe stages in some infants while in others, despite similar clinical conditions, it regresses spontaneously.

We hypothesised that a plausible explanation might be the interplay of the genetic factors and predisposition to inflammation. Our results indicate the association between intrauterine infection and ROP development, which supports the hypothesis of inflammation-related pathogenetic mechanisms underlying the development of ROP. ELGAN [26] and many other studies support the concept that neonatal sepsis is a risk factor for any stage ROP as well as severe ROP [13, 27]. Also, Sood et al. [28], who studied cytokine levels in extremely low birth weight newborns and showed that some cytokines remained significantly different across ROP groups, concluded that perinatal inflammation may be involved in the pathogenesis of ROP.

Other researchers confirmed a strong genetic predisposition to ROP. Bizzarro et al. [29] analysed 63 monozygotic and 137 dizygotic twin pairs and reached the conclusion that genetic factors accounted for 70.1% of the variance in liability for retinopathy of prematurity. Similarly, in the Ortega-Molina et al. study [30] heritability of ROP was found to be 72.8%.

We linked these two discoveries and based our research hypothesis on the premise that genetic predisposition may impact the susceptibility to inflammation and in turn might be a key factor that either predisposes or protects against ROP. To date, little attention has been given to polymorphisms of inflammation-associated genes and the development of ROP. To our knowledge, there has been no study investigating IL-1RN and IL-6 gene polymorphism in preterm infants with ROP so far.

Our most important finding from the analysis of the occurrence of studied polymorphisms was that IL-1 receptor antagonist genotype distribution differs significantly among the patients with ROP who did not require treatment and those in whom treatment was necessary. IL-1 receptor antagonist is a competitive inhibitor of IL-1-induced pro-inflammatory activity. Its encoding gene is polymorphic, resulting in quantitative differences in production of both IL-1 receptor antagonist and IL-1β [31]. The VNTR polymorphism occurs within intron 2 of the human IL-1RN gene and consists of repeats of an 86-bp sequence. The number of repeats is of functional significance because these repeats contain binding sites for transcription factors [32]. In our study, the IL-1RN VNTR polymorphism was distributed with a higher proportion of rare 2/2 genotype in the group of patients who required treatment. Conversely, a more frequent occurrence of major 1/1 genotype was found in patients with ROP that regressed spontaneously. Interestingly, the 2/2 genotype was also found in the only infant from our study group who required retreatment due to ROP recurrence. This would suggest the possible connection between the 2/2 genotype and a more severe course of ROP. This finding is in accordance with the study of Witkin [31], who reported that prolonged and more intense pro-inflammatory response is observed in homozygote IL1-RN gene 2 allele (IL1-RN*2). Similar to Dammann et al. [16], we also found that genetic markers, in our case IL-1RN VNTR polymorphism, were not associated with ROP occurrence, but with progression to the high-grade disease. This may be an indication that already susceptible infants’ may possess a genetic predisposition that makes them vulnerable to infection and subsequently puts them at even greater risk of progression of ROP.

The analysis revealed also that there was a higher proportion of the 2/2 IL-1RN genotype in patients with ROP and intrauterine infection compared to ROP patients without intrauterine infection. This finding requires further research in a larger study group.

We also analysed IL-1β+3953 C>T and TNF-α-308 G>A gene polymorphisms due to the pro-inflammatory properties of IL-1 and TNF-α cytokines. Previous studies evaluating IL-1β and TNF-α plasma levels observed inconsistent results on whether they are involved in the development of proliferative retinopathies. Mysliwiec et al. [33], Gardner et al. [34], and Meleth et al. [35] reported elevated levels of IL-1β and TNF-α in diabetic retinopathy. Conversely, the large population-based study of Sood et al. [28] did not find these cytokines to be significantly associated with ROP severity. The genetic exploratory analyses of Dammann et al. [16] suggest a trend toward protection in occurrence, but a risk increase in ROP progression with the presence of IL-1β and TNF-α SNPs. Similar to Türe et al. [36], our study showed no correlation between TNF-α-308 G>A gene polymorphisms and susceptibility to ROP. Also, as in the study by Cook et al. [37], there was no significant difference for TNF-α-308 G>A polymorphism distribution between preterm infants who received treatment for threshold ROP and infants who did not. Neither did our data demonstrate any predictive value for the IL-1β+3953 C>T polymorphism increasing the risk of ROP development/progression in preterm infants.

To date there have been no studies assessing the link between IL-6 -174 G>C and IL-6 -596 G>A polymorphism and ROP. Previous research indicates only that in preterm infants, development of ROP was associated with elevated levels of IL-6 [28]. The replacement of guanine with cytosine at position -174 of the IL-6 gene results in diminished production of IL6 in homozygous CC individuals. Similarly, the replacement of guanine by adenosine at position -596 causes decreased IL-6 production by AA homozygotes. Our analysis did not find an association between either the IL-6 -174 G>C or the IL-6 -596 G>A polymorphism genotypes and ROP; this has not been reported previously. However, we observed a significant deviation from Hardy-Weinberg equilibrium for both IL-6 polymorphisms for ROP patients, for ROP patients with intrauterine infection, and for the patients without intrauterine infection; the deviation was also present for IL-6 -596 G>A polymorphism for ROP patients not requiring treatment, which might indicate the association of these polymorphisms with the occurrence of disease. This finding requires further research in a larger study group.

The limitations of our study include the relatively small sample size, which did not allow for further statistical analyses, and the lack of measurement of plasma levels of IL-1, IL-6, TNF-α, and IL-1RA cytokines, which precludes the possibility of relating specific polymorphisms and their expression in studied patients. Thus, our study demonstrates preliminary results, which should be confirmed by further research.

Conclusions

The results of our study support the idea that retinopathy of prematurity is a multifactorial disease in which environmental (e.g. BW, GA, mechanical ventilation) and genetic risk factors (genotype 2/2 IL-1RN) interact. Future investigations of polymorphisms in inflammation-associated genes, especially in IL-1RN VNTR 86 bp, may provide valuable insight into the pathogenic mechanisms underlying the development of ROP and help to identify the most susceptible infants and treat ROP even more effectively.